Cerebrospinal Fluid Tissue Transglutaminase as a Biochemical Marker for Alzheimer's Disease

Cerebrospinal Fluid Tissue Transglutaminase as a Biochemical Marker for Alzheimer's Disease

Tissue transglutaminase (tTG) is an indicator of acute cell death in vitro. An increase in tTG protein level is found in postmortem Alzheimer's disease (AD) brains as well as in Huntington's disease. No study revealed tTG in vivo so far. We investigated the concentrations of tTG in the cer...

Full description

Bibliographic Details
Main Authors:	Raphael M. Bonelli, Andreas Aschoff, Gerald Niederwieser, Clemens Heuberger, Gustaf Jirikowski
Format:	Article
Language:	English
Published:	Elsevier 2002-10-01
Series:	Neurobiology of Disease
Subjects:	Alzheimer's disease tissue transglutaminase apoptosis vascular dementia tau protein
Online Access:	http://www.sciencedirect.com/science/article/pii/S0969996102905358

Similar Items

Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease—From Brain Starch to Bench and Bedside
by: Matthias Pawlowski, et al.
Published: (2017-07-01)

Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer’s Disease and Other Neurological Disorders
by: Giovanni Bellomo, et al.
Published: (2021-03-01)

A Novel Model of Mixed Vascular Dementia Incorporating Hypertension in a Rat Model of Alzheimer’s Disease
by: Paul Denver, et al.
Published: (2019-10-01)

Cerebrospinal Fluid Alzheimer Markers in Depressed Elderly Subjects with and without Alzheimer’s Disease
by: Milica Gregoric Kramberger, et al.
Published: (2012-03-01)

Cerebrospinal Fluid Biomarkers for Differentiation of Frontotemporal Lobar Degeneration from Alzheimer’s Disease
by: David J Irwin, et al.
Published: (2013-02-01)

Cerebrospinal Fluid Biomarkers in Diagnosing Alzheimer’s Disease in Clinical Practice: An Illustration with 3 Case Reports
by: Diane Slats, et al.
Published: (2010-02-01)

PET Imaging of Tau Pathology: Towards an affirmative diagnosis of Alzheimer’s and Tauopathies
by: Olga eJames, et al.
Published: (2015-03-01)

Loss of DEK Expression Induces Alzheimer’s Disease Phenotypes in Differentiated SH-SY5Y Cells
by: Allie N. Greene, et al.
Published: (2020-11-01)

Cerebrospinal fluid P-tau181P: biomarker for improved differential dementia diagnosis
by: Hanne eStruyfs, et al.
Published: (2015-06-01)

2015: which new directions for Alzheimer’s disease?
by: Xénia eLATYPOVA, et al.
Published: (2014-12-01)

Development of a Differential Neurocognitive Profile for Alzheimer’s Dementia and Vascular Dementia
by: Hill, Jonathan
Published: (2013)

The temperature and pH repertoire of the transglutaminase family is expanding
by: Aaron Lerner, et al.
Published: (2020-04-01)

Arylesterase Activity of Paraoxonase-1 in Serum and Cerebrospinal Fluid of Patients with Alzheimer’s Disease and Vascular Dementia
by: Arianna Romani, et al.
Published: (2020-05-01)

Dementia-associated changes of immune cell composition within the cerebrospinal fluid
by: Stefan Busse, et al.
Published: (2021-07-01)

Vascular Endothelial Growth Factor remains unchanged in cerebrospinal fluid of patients with Alzheimer’s disease and vascular dementia
by: Ananya Chakraborty, et al.
Published: (2018-06-01)

Alzheimer’s disease models and functional genomics - How many needles are there in the haystack?
by: Jurgen eGotz, et al.
Published: (2012-08-01)

The importance of transglutaminase in tumour growth and metastasis
by: Hand, D.
Published: (1988)

Cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer’s disease
by: Carolina A. Magalhães, et al.
Published: (2015-12-01)

Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease: Current Evidence and Future Perspectives
by: Donovan A. McGrowder, et al.
Published: (2021-02-01)

Don’t forget the exogenous microbial transglutaminases: it is immunogenic and potentially pathogenic
by: Aaron Lerner, et al.
Published: (2016-11-01)

Detection of oral transglutaminases and their relevance in celiac disease
by: Shen, Shiqian
Published: (2018)

Neurofilaments and tau proteins in cerebrospinal fluid and serum in dementias and neuroinflammation
by: Lenka Fialova, et al.
Published: (2017-09-01)

Neuroimaging techniques for diagnosing Alzheimer’s disease and cerebrovascular diseases with cognitive impairment
by: I. V. Litvinenko, et al.
Published: (2019-06-01)

Transglutaminase 2 as a Marker for Inflammation and Therapeutic Target in Sepsis
by: Ting Su, et al.
Published: (2021-02-01)

Physicochemical properties of three food proteins treated with transglutaminase Propriedades físico-químicas de três proteínas alimentares tratadas com transglutaminase
by: Luís Henrique de Barros Soares, et al.
Published: (2004-08-01)

Editorial: Tau Pathology in Neurological Disorders
by: Sonia Do Carmo, et al.
Published: (2021-09-01)

Biotechnological Applications of Transglutaminases
by: Joelle N. Pelletier, et al.
Published: (2013-10-01)

Race modifies the relationship between cognition and Alzheimer’s disease cerebrospinal fluid biomarkers
by: Jennifer C. Howell, et al.
Published: (2017-11-01)

Editorial: Untangling the Role of Tau in Physiology and Pathology
by: Miguel Medina, et al.
Published: (2020-05-01)

A new TAO kinase inhibitor reduces tau phosphorylation at sites associated with neurodegeneration in human tauopathies
by: Caterina Giacomini, et al.
Published: (2018-05-01)

Produção de transglutaminase de Streptomyces sp. P20 = caracterização da enzima bruta
by: Bagagli, Marcela Pavan, 1981-
Published: (2009)

Cerebrospinal fluid from Alzheimer’s disease patients promotes tau aggregation in transgenic mice
by: Zhiva Skachokova, et al.
Published: (2019-05-01)

Neurological Mechanisms of Animal-Assisted Intervention in Alzheimer’s Disease: A Hypothetical Review
by: Sujin Kim, et al.
Published: (2021-07-01)

Alzheimer’s associated amyloid and tau deposition co-localizes with a homeostatic myelin repair pathway in two mouse models of post-stroke mixed dementia
by: Thuy-Vi V. Nguyen, et al.
Published: (2018-09-01)

Extraction, partial purification and characterization of transglutaminase from the liver of bluefish (Pomatomus saltatrix)
by: Subramanian, Vidya.
Published: (2008)

Can visuospatial measures improve the diagnosis of Alzheimer's disease?
by: Shirin Salimi, et al.
Published: (2018-01-01)

Role of neuropsychological assessment in the differential diagnosis of Alzheimer's disease and vascular dementia
by: Érica Maria Lima Pimentel

Cerebrospinal fluid biomarkers of Alzheimer's disease in a cohort of adults with Down syndrome
by: Rachel L. Henson, et al.
Published: (2020-01-01)

Significance of Blood and Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: Sensitivity, Specificity and Potential for Clinical Use
by: Cristina d’Abramo, et al.
Published: (2020-09-01)

Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer’s disease and PET amyloid-positive patient identification
by: Nicolas R. Barthélemy, et al.
Published: (2020-03-01)